2008 - Fellow of the American Association for the Advancement of Science (AAAS)
His main research concerns Interferon, Immunology, Internal medicine, Cancer research and Molecular biology. His Interferon research incorporates elements of Biochemistry, Cell cycle, Macrophage, Pharmacology and Indoleamine 2,3-dioxygenase. He usually deals with Immunology and limits it to topics linked to Mechanism of action and Signal transduction, Cell culture, Allogeneic Lymphocyte and Hairy cell leukemia.
His Internal medicine research integrates issues from Surgery, Endocrinology, Alpha interferon and Oncology. His specific area of interest is Cancer research, where Ernest C. Borden studies Melanoma. His studies in Molecular biology integrate themes in fields like Peripheral blood mononuclear cell, In vitro, Interferon gamma, Lymphocyte and Monocyte.
Interferon, Immunology, Cancer research, Internal medicine and Melanoma are his primary areas of study. His Interferon study integrates concerns from other disciplines, such as Molecular biology, In vitro, Biochemistry and Pharmacology. The Molecular biology study combines topics in areas such as Lymphokine-activated killer cell and Lymphocyte.
His Immunology study often links to related topics such as Peripheral blood mononuclear cell. His Cancer research study deals with Pathology intersecting with Circulating tumor cell. His biological study spans a wide range of topics, including Endocrinology, Alpha interferon and Oncology.
His scientific interests lie mostly in Cancer research, Cancer, Melanoma, Internal medicine and Oncology. The concepts of his Cancer research study are interwoven with issues in Interferon, Pathology, Receptor, Signal transduction and Programmed cell death. His Interferon research is multidisciplinary, incorporating elements of Flow cytometry and Gene.
His Melanoma research incorporates themes from Cell growth, Immunology, Immune system, Renal cell carcinoma and In vivo. Ernest C. Borden interconnects Endocrinology, Medical physics and Sarcoma in the investigation of issues within Internal medicine. His Oncology study combines topics in areas such as Clinical trial, Phases of clinical research, Survival rate, Surgery and Apoptosis.
Ernest C. Borden mostly deals with Cancer research, Melanoma, Internal medicine, Interferon and Immune system. Ernest C. Borden combines subjects such as Histone deacetylase, Histone deacetylase 5, Signal transduction and Autocrine signalling with his study of Cancer research. His Melanoma research incorporates elements of Open Resection, Endoscopy and In vivo.
His research integrates issues of Virus, Endocrinology and Oncology in his study of Internal medicine. His Interferon research focuses on Gene and how it connects with Cytokine, Cell type and Cancer cell. His Immune system study introduces a deeper knowledge of Immunology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
John M. Kirkwood;Myla Hunt Strawderman;Marc S. Ernstoff;Thomas J. Smith.
Journal of Clinical Oncology (1996)
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
Charles D. Blanke;Cathryn Rankin;George D. Demetri;Christopher W. Ryan.
Journal of Clinical Oncology (2008)
Interferons at age 50: past, current and future impact on biomedicine.
Ernest C Borden;Ganes Sen;Gilles Uze;Robert H Silverman.
Nature Reviews Drug Discovery (2007)
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.
Mamta Chawla-Sarkar;Daniel J Lindner;Y-F Liu;Bryan Raymond George Williams.
Circulating Tumor Cells versus Imaging—Predicting Overall Survival in Metastatic Breast Cancer
G. Thomas Budd;Massimo Cristofanilli;Mathew J. Ellis;Allison Stopeck.
Clinical Cancer Research (2006)
Inhibition of Angiogenesis by Interferons: Effects on Tumor-and Lymphocyte-induced Vascular Responses
Younan A. Sidky;Ernest C. Borden.
Cancer Research (1987)
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Michael C. Heinrich;Kouros Owzar;Christopher L. Corless;Donna Hollis.
Journal of Clinical Oncology (2008)
Biological Properties of Recombinant α-Interferons: 40th Anniversary of the Discovery of Interferons
Lawrence M. Pfeffer;Charles A. Dinarello;Ronald B. Herberman;Bryan R. G. Williams.
Cancer Research (1998)
Soft Tissue Sarcomas of Adults State of the Translational Science
Ernest C. Borden;Laurence H. Baker;Robert S. Bell;Vivien Bramwell.
Clinical Cancer Research (2003)
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.
M Chawla-Sarkar;S I Bae;F J Reu;B S Jacobs.
Cell Death & Differentiation (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: